Foundation Professor weighs in on the Novavax COVID-19 vaccine

Vivian Riefberg, the David C. Walentas Jefferson Scholars Foundation Professor at U.Va.’s Darden School of Business, weighs in on the possible approval of Novavax’s fourth COVID-19 vaccine shot. Vivian is a retired senior partner with McKinsey & Company and has written extensively on government productivity and improving U.S. healthcare.